Focus Issue: Therapeutic ConsiderationsClinical ResearchDapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
Clinical Research
Under an Elsevier user license
open archive
Central Illustration
Key Words
aldosterone
dapagliflozin
heart failure
hyperkalemia
kidney function
mineralocorticoid receptor antagonist
potassium
SGLT2 inhibitor
Abbreviations and Acronyms
CI
confidence interval
eGFR
estimated glomerular filtration rate
HF
heart failure
HFrEF
heart failure with reduced ejection fraction
HR
hazard ratio
LVEF
left ventricular ejection fraction
MRA
mineralocorticoid receptor antagonist
NT-proBNP
N-terminal pro–B-type natriuretic peptide
NYHA
New York Heart Association
SBP
systolic blood pressure
SGLT2
sodium glucose co-transporter 2
Cited by (0)
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 Published by Elsevier on behalf of the American College of Cardiology Foundation